AbbVie (ABBV) News Today

AbbVie Inc. (NYSE: ABBV) is drawing investor attention after a series of positive catalysts, led by FDA approval of Decnupaz (pivekimab sunirine-pvzy) for blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer. The approval gives AbbVie its first ADC approved for a blood cancer and could help expand its oncology franchise, which has been under pressure from older drugs like Imbruvica.

• Positive Sentiment: AbbVie won FDA approval for Decnupaz in BPDCN, adding a new ultra-rare blood cancer treatment and strengthening its oncology pipeline. Reuters: US FDA approves AbbVie's rare blood cancer drug
• Positive Sentiment: The company also launched a first-in-human Phase 1 study for ABBV-1451, signaling continued early-stage pipeline development that could support longer-term growth. TipRanks: AbbVie Expands Early Pipeline With New First-in-Human Study for ABBV-1451
• Positive Sentiment: Analysts remain constructive, with Piper Sandler raising its price target on AbbVie and citing progress in the company’s inflammatory bowel disease pipeline. Yahoo Finance: Piper Sandler Raises Price Target on AbbVie
• Neutral Sentiment: AbbVie’s oncology portfolio showed mixed Q1 performance, with declining Imbruvica sales offset by gains from Venclexta, Elahere, and Epkinly. Zacks: How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?

Overall, ABBV appears to be trading higher on optimism around the newly approved cancer drug, pipeline expansion, and supportive analyst commentary.